ArticleMedicine2026
Core targets of bisphenol A in cervical cancer revealed by network toxicology and molecular docking.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacovigilance and network toxicology analysis of risdiplam-associated adverse events in pediatric patients with spinal muscular atrophy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the molecular mechanisms underlying BPA(Bisphenol A)-induced cervical cancer, to identify core targets and signaling pathways, and to provide a theoretical basis for disease prevention and therapeutic intervention. The chemical structure of BPA was obtained from PubChem(Public Chemical Database), and its toxicity profile was evaluated using ProTox-3.0. Potential BPA-associated targets were predicted using multiple databases and subsequently standardized. Differentially expressed genes (DEGs) in cervical cancer were identified from Gene Expression Omnibus datasets using the R programming language and integrated with Weighted Gene Co-expression Network Analysis (WGCNA) to determine key module genes. The cervical cancer-related target set was then established. Common targets between BPA and cervical cancer were identified using Venn diagram analysis, and a protein-protein interaction (PPI) network was constructed to screen for core targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to explore biological functions and pathways. Target gene expression was validated across multiple datasets, and molecular docking analysis was conducted using Cavity-Based Dock 2 (CB-Dock2). BPA exhibits endocrine toxicity and matrix metalloproteinase-mediated tissue damage, with 3 core targets identified across databases. In cervical cancer, 803 up-regulated and 1092 down-regulated DEGs were screened (|log2FC| ≥1, adjusted P <.05). WGCNA identified the turquoise module (normal group R = 0.98, P = 5 × 10-12; cancer group r = -0.98, P = 5 × 10-12), overlapping with 1110 DEGs. Nineteen common targets of BPA and cervical cancer were enriched in gene expression negative regulation and cancer pathways (hypergeometric test, false discovery rate (FDR) <0.05). PPI analysis confirmed Estrogen Receptor 1 (ESR1) and (Poly [ADP-ribose] Polymerase 1 (PARP1) as core targets: ESR1 was down-regulated (GSE122697: log2FC = -2.8, P <.0001; The Cancer Genome Atlas (TCGA): log2FC = -2.6, P <.0001), PARP1 up-regulated (GSE122697: log2FC = 3.1, P <.0001; TCGA: log2FC = 2.9, P = .0012). Both showed progressive expression changes with lesion advancement (GSE63514: ESR1 log2FC = -4.2, PARP1 log2FC = 4.5, P <.0001). Molecular docking revealed stable binding of BPA to ESR1 (-8.3 kcal/mol) and PARP1 (-8.5 kcal/mol, root-mean-square deviation [RMSD] <2.0 A). BPA may promote cervical carcinogenesis by interacting with ESR1 and PARP1 to regulate key cancer-related pathways. These targets may serve as potential biomarkers and therapeutic intervention points. Further experimental validation is required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.